

Programma ECM

1st Treviso Lung Day Marca Trevigiana - From Standards of diagnosis to novel treatment options -

Aula Convegni Ospedale Cà Foncello, Treviso, Italy

June 7th-8th, 2019

> Chair: Dr.ssa Micaela Romagnoli

> Scientific Committee:

Fabio De Conti Riccardo Drigo Paolo Lucernoni Lucio Michieletto Manuele Nizzetto

Scientific Secretariat:

Cosimo Catino Elisabetta Marcon Francesca Savoia Giuseppe Zanardi

Addressees: 80 MEDICAL SPECIALISTS in Respiratory Diseases, Internal Medicine, General Medicine, General Surgery, Pathological Anatomy, Radiodiagnostics.

Rationale

The aim of the present 1st Edition of "Treviso Lung Day" is to provide an overview of where the Respiratory clinicians are on a few main topics in respiratory diseases: obstructive lung diseases (asthma, severe asthma, and COPD), lung cancer, and interstitial lung diseases.

The first 2 sessions of the first day will focus on the recent major advancements on asthma phenotyping, with a particular interest on severe asthma, and novel innovative pharmacological antiasthmatic modalities and treatments. Asthma is a very common chronic airway inflammatory disorder, affecting the 5-10% of the whole population, with the subset of "severe asthma" which counts the highest impact on patients' quality of life, and the highest social impact for asthma.

A Lettura Magistrale will present what is the update on the optimal lung cancer diagnosis and novel treatment approach, which require a multidisciplinary team of specialists who care for a significant number of patients on a regular basis. Lung cancer carries a huge disease burden: the death toll is high,



the disease severely impacts the quality of life of patients and their families, and it is associated with considerable costs for patients and health systems.

The afternoon sessions will be dedicated to the very important issue of patients with COPD, with a particular emphasis to the more optimistic view that multiple drug combination, and rehabilitative and ventilatory approach to the severe COPD patients might prolong their life expectancy, and not only improve their symptoms and quality of life.

The 2 sessions of the 2nd day will entirely focus on interstitial lung diseases, especially on Idiopathic Pulmonary Fibrosis (IPF), which is the most common form of interstitial lung disease, and which is associated with high morbidity and mortality with a reported median survival of approximately three years. The speakers will highlight the complexity of the diagnostic approach of this disease, since many challenges exist, particularly in relation to diagnosis, clinical phenotyping and treatment options, including pharmacologic treatments and lung transplant.

The invited speakers, national and international, have in common an exceptional scientific production specific to the topics they deal with, documented by their publications on the most prestigious international journals in the field.

The meeting will represent a unique opportunity to interact with the most national and international experts of these topics, in the historical town of Treviso cited by Dante in the Divina Commedia, in the vicinity of spectacular Venice, in the beautiful Veneto region with its amazing landscapes!

SCIENTIFIC PROGRAM

1st DAY – Friday, June 7

h. 9.30 Registration of participants

h. 10.00 Welcome and Introduction to the Meeting

Dr. Francesco Benazzi, General Director, AULSS 2 Marca Trevigiana

Dr.ssa Micaela Romagnoli, Treviso

Asthma and Severe Asthma – Update on new pharmacological modalities and new treatments

1st SESSION

Chairmen: Andrea Vianello (Padova), Gian Enrico Senna (Verona), Silvia Tognella (Legnago, VR)

- h. 10.30 What are the relevant endotypes of asthma, and what biomarkers do we have available?

 Arnaud Bourdin (Montpellier, France)
- h. 11.00 Definition of a complex and heterogenous disease: severe asthma. Fabio Ricciardolo (Torino)
- h. 11.30 What do national and international guidelines say about severe asthma? Claudio Micheletto (Legnago, VR)



2nd SESSION

Chairmen: Alberto Papi (Ferrara) Micaela Romagnoli (Treviso), Isabelle Vachier (Montpellier)

- h. 12.00 Who needs ICS in asthma?

 Alberto Papi (Ferrara)
- h. 12.30 Biologic treatments in type2-severe asthma: an overview on the most relevant data Pascal Chanez (Marseille, France)
- h. 13.00 New options for severe asthma: what patients, what agents, what results, at what cost? Klaus F. Rabe (Grosshansdorf, Germany)
- h.13.30 Light Lunch
- h. 14.30 Lectio Magistralis: Lung cancer: A Whole New World
 Klaus F. Rabe (Grosshansdorf, Germany)
 Introduction Micaela Romagnoli

COPD – Update on pathogenesis and pharmacological treatments

1st SESSION

Chairmen: Marina Saetta (Padova), Guido Polese (Bussolengo, VR), Fabio Vassallo (Gorizia)

- h. 15.30 Immunologic aspects of COPD and the role of eosinophils

 Manuel Cosio (Padova)
- h. 16.00 Understanding exacerbations of COPD Leonardo M. Fabbri (Modena)
- h. 16.30 Aspects of severe COPD Stefano Nava (Bologna)
- h. 17.00 Coffee Break

2nd SESSION

Chairmen: Bianca Beghè (Modena), Antonio Spanevello (Varese), Giorgio Santelli (Motta di Livenza, TV)

h. 17.30 Non-pharmacological treatment and rehabilitation Enrico Clini (Modena)

Eolo Group Eventi srl



h. 18.00 Chronic bronchitis, COPD, emphysema, ACO (please help!)

Marco Contoli (Ferrara)

h. 18.30 Therapy for COPD: Mono – Dual – Triple.. and?

Alberto Papi (Ferrara)

h. 19.00 End of the 1st day sessions

Dinner

2nd DAY – Saturday, June 8

Interstitial Lung Disease – Update in the diagnosis and management

1st SESSION

Chairmen: Fiorella Calabrese (Padova), Marco Confalonieri (Trieste), Francesco Mazza (Pordenone)

- h. 8.30 The clinical diagnosis and the multidisciplinary approach of ILDs Paolo Spagnolo (Padova)
- h. 9.00 Airways and interstitial lung abnormalities, and correlations with IPF Sara Piciucchi (Forlì)
- h. 9.30 Pathology of ILDs: challenges
 Thomas V. Colby (Scottsdale, Arizona)
- h. 10.00 Diagnosis of ILDs and IPF: challenges for the clinician and for the bronchoscopist Alfons Torrego (Barcellona)
- h. 10.30 Coffee Break

2nd SESSION

Chairmen: Carlo Agostini (Treviso), Elisabetta Balestro (Padova), Stefano Calabro (Bassano del Grappa, VI)

h. 11.00 What if it is not IPF? Venerino Poletti (Forlì)

Eolo Group Eventi srl



- h. 11.30 Lung transplant in IPF: the best candidates, the best timing, the best pretransplant treatment **Federico Rea (Padova)**
- h. 12.00 A review of pharmacological management of IPF and progressive-fibrosing interstitial lung disease: present and future

 Luca Richeldi (Roma)
- h. 12.30 Conclusions and ECM Questionnaire
- h. 13.00 Light Lunch
 - > Training hours: 12 hours